// MedKitt — A-Fib RVR (Atrial Fibrillation with Rapid Ventricular Response) Consult
// Initial assessment → hemodynamic stability → rate/rhythm control → anticoagulation → disposition.
// 6 modules: Initial Assessment → Unstable Pathway → Rate Control → Refractory → Anticoagulation → Disposition
// 20 nodes total.

import type { DecisionNode } from '../../models/types.js';
import type { Citation } from './neurosyphilis.js';

export const AFIB_RVR_NODES: DecisionNode[] = [

  // =====================================================================
  // MODULE 1: INITIAL ASSESSMENT
  // =====================================================================

  {
    id: 'afib-start',
    type: 'info',
    module: 1,
    title: 'A-Fib RVR: Initial Assessment',
    body: '[A-Fib RVR Management Steps](#/info/afib-summary) \u2014 quick-reference for rate control, cardioversion, and anticoagulation.\n\nAtrial fibrillation with rapid ventricular response (RVR) is characterized by an irregularly irregular rhythm with a ventricular rate typically 120\u2013180 bpm. Confirm with 12-lead ECG.\n\nCOMMON PRECIPITANTS\n\u2022 Electrolyte abnormalities (K\u207a, Mg\u00b2\u207a)\n\u2022 Sepsis / infection\n\u2022 Pulmonary embolism\n\u2022 Thyrotoxicosis\n\u2022 Alcohol use / withdrawal\n\u2022 Pain / agitation\n\u2022 Respiratory failure / hypoxia\n\u2022 Underlying cardiac disease (valvular, ischemic, HF)\n\nAlways treat underlying causes alongside rate control. A-Fib RVR is often a symptom of another process \u2014 rate control alone may be insufficient if the precipitant is not addressed.',
    citation: [1, 3],
    next: 'afib-stability',
  },

  {
    id: 'afib-stability',
    type: 'question',
    module: 1,
    title: 'Hemodynamic Stability',
    body: 'Is the patient hemodynamically stable?',
    options: [
      {
        label: 'Hemodynamically stable',
        description: 'Adequate BP, perfusion, no acute HF or ischemia',
        next: 'afib-ef-screen',
      },
      {
        label: 'Hemodynamically unstable',
        description: 'Hypotension, acute HF, ongoing ischemia, altered mental status, or shock',
        next: 'afib-unstable-wpw',
        urgency: 'critical',
      },
    ],
  },

  {
    id: 'afib-ef-screen',
    type: 'question',
    module: 1,
    title: 'Ejection Fraction Assessment',
    body: 'Does the patient have reduced ejection fraction (EF ≤40%)?\n\nThis is critical for rate control agent selection. Calcium channel blockers (diltiazem, verapamil) are **contraindicated** in HFrEF (Class 3: Harm).\n\nCheck:\n• Prior echocardiogram\n• Known history of HFrEF or systolic heart failure\n• Bedside echo if available and EF unknown',
    options: [
      {
        label: 'EF ≤40% or HFrEF',
        description: 'Known reduced EF, systolic HF, or dilated cardiomyopathy',
        next: 'afib-hfref-drugs',
        urgency: 'urgent',
      },
      {
        label: 'EF >40% or preserved',
        description: 'Normal EF, HFpEF, or no known cardiomyopathy',
        next: 'afib-stable-drugs',
      },
      {
        label: 'EF unknown',
        description: 'No recent echo available - will proceed cautiously',
        next: 'afib-ef-unknown',
      },
    ],
  },

  {
    id: 'afib-ef-unknown',
    type: 'info',
    module: 1,
    title: 'Unknown EF — Proceed with Caution',
    body: 'EF IS UNKNOWN — SAFE APPROACH\n\nWhen EF is unknown, avoid calcium channel blockers (diltiazem, verapamil) until EF is confirmed >40%.\n\n**Safe first-line options regardless of EF:**\n• [Metoprolol](#/drug/metoprolol) 2.5–5 mg IV q5min (use lower doses if concerned for HF)\n• [Esmolol](#/drug/esmolol) — ultra-short-acting, can rapidly titrate off if hemodynamics worsen\n• IV [Magnesium Sulfate](#/drug/magnesium-sulfate) 2–4g — excellent safety profile\n\n**If possible, obtain bedside echo:**\n• Eyeball EF (normal >55%, mildly reduced 40-55%, reduced ≤40%)\n• [EPSS measurement](#/info/epss-measurement) correlates with EF\n• Look for dilated LV, global hypokinesis\n\nOnce EF is clarified, you can safely add CCBs if EF >40%.',
    citation: [1, 2],
    treatment: {
      firstLine: {
        drug: 'Metoprolol',
        dose: '2.5-5 mg',
        route: 'IV',
        frequency: 'q5min',
        duration: 'Up to 15 mg total',
        notes: 'Use lower doses if concerned for HF',
      },
      alternative: {
        drug: 'Esmolol',
        dose: '500 mcg/kg bolus, then 50-200 mcg/kg/min',
        route: 'IV',
        frequency: 'Continuous infusion',
        duration: 'Until rate controlled',
        notes: 'Ultra-short-acting, can rapidly titrate off if hemodynamics worsen',
      },
      monitoring: 'Heart rate, blood pressure, signs of decompensation. Obtain bedside echo to clarify EF when possible.',
    },
    next: 'afib-rate-controlled',
  },

  {
    id: 'afib-hfref-drugs',
    type: 'info',
    module: 3,
    title: 'Rate Control in HFrEF (EF ≤40%)',
    body: 'RATE CONTROL IN HEART FAILURE WITH REDUCED EF\n\n⚠️ **CONTRAINDICATED in HFrEF:**\n• Diltiazem — Class 3: Harm\n• Verapamil — Class 3: Harm\n• Non-dihydropyridine CCBs worsen HF outcomes and increase mortality\n\n**FIRST-LINE — Beta-Blockers:**\n• [Metoprolol](#/drug/metoprolol) 2.5–5 mg IV q5min, up to 15 mg total\n• Use lower initial doses in decompensated HF\n• [Esmolol](#/drug/esmolol) if rapid titration needed or hemodynamic uncertainty\n• Beta-blockers are guideline-directed therapy for HFrEF — safe when carefully dosed\n\n**SECOND-LINE — Digoxin:**\n• [Digoxin](#/drug/digoxin) 0.25–0.5 mg IV\n• Particularly useful in HFrEF — positive inotropic effect may be beneficial\n• Slow onset (~3 hours) — use as adjunct, not sole agent\n• Use low doses to avoid toxicity\n\n**ALTERNATIVE — Amiodarone:**\n• [Amiodarone](#/drug/amiodarone) 150 mg IV bolus, then 1 mg/min\n• Hemodynamically stable, safe in HFrEF\n• May achieve chemical cardioversion\n• Consider if beta-blocker contraindicated or insufficient\n\n**ADJUNCTIVE:**\n• IV [Magnesium Sulfate](#/drug/magnesium-sulfate) 2–4g — safe in all patients',
    citation: [1, 2, 3],
    treatment: {
      firstLine: {
        drug: 'Metoprolol',
        dose: '2.5-5 mg',
        route: 'IV',
        frequency: 'q5min',
        duration: 'Up to 15 mg total',
        notes: 'Use lower initial doses in decompensated HF. Guideline-directed therapy for HFrEF.',
      },
      alternative: {
        drug: 'Amiodarone',
        dose: '150 mg bolus, then 1 mg/min infusion',
        route: 'IV',
        frequency: 'Bolus over 10 min, then continuous',
        duration: 'Until rate controlled or cardioversion achieved',
        notes: 'Hemodynamically stable, safe in HFrEF. May achieve chemical cardioversion.',
      },
      monitoring: 'Heart rate, blood pressure, signs of HF decompensation. Avoid CCBs (Class 3: Harm).',
    },
    next: 'afib-hfref-controlled',
  },

  {
    id: 'afib-hfref-controlled',
    type: 'question',
    module: 3,
    title: 'HFrEF Rate Control Assessment',
    body: 'Is the ventricular rate now controlled?\n\nTarget heart rate in HFrEF:\n• <110 bpm is reasonable initial target\n• Titrate to symptom control — some patients tolerate higher rates\n• Avoid aggressive rate control that worsens cardiac output\n• If hypotensive, prioritize digoxin + amiodarone over beta-blockers',
    options: [
      {
        label: 'Yes — Rate controlled',
        description: 'Heart rate at target, symptoms improved',
        next: 'afib-onset-assessment',
      },
      {
        label: 'No — Rate still uncontrolled',
        description: 'Heart rate remains above target despite first-line agent',
        next: 'afib-hfref-refractory',
        urgency: 'urgent',
      },
    ],
  },

  {
    id: 'afib-hfref-refractory',
    type: 'question',
    module: 4,
    title: 'HFrEF — Refractory Rate Control',
    body: 'Select second-line intervention for refractory rate control in HFrEF.\n\n⚠️ Remember: Calcium channel blockers remain **contraindicated**.\n\nRe-evaluate for underlying causes (volume overload, ischemia, infection). Ensure adequate trial of first-line agent.',
    options: [
      {
        label: 'Add Digoxin',
        description: 'Positive inotropy may help in HFrEF. Use if beta-blocker causing hypotension.',
        next: 'afib-refractory-dig',
      },
      {
        label: 'Add IV Magnesium',
        description: 'Safe adjunct. Blocks slow Ca channels at AV node.',
        next: 'afib-refractory-mg',
      },
      {
        label: 'Switch to Amiodarone',
        description: 'Hemodynamically stable. May achieve cardioversion.',
        next: 'afib-refractory-amio',
      },
      {
        label: 'Consider Cardioversion',
        description: 'When rate control strategy has failed in decompensated HF.',
        next: 'afib-hfref-cardioversion',
      },
    ],
  },

  {
    id: 'afib-hfref-cardioversion',
    type: 'info',
    module: 4,
    title: 'Cardioversion in HFrEF',
    body: 'RHYTHM CONTROL IN HFrEF\n\nCardioversion may be particularly beneficial in HFrEF:\n• Loss of atrial kick worsens cardiac output\n• Tachycardia-induced cardiomyopathy may be reversible\n• Rhythm control may improve HF symptoms\n\n**Procedure:**\n1. Sedation with [Midazolam](#/drug/midazolam) or ketamine/midazolam\n2. Synchronized cardioversion at 200J biphasic\n3. [Amiodarone](#/drug/amiodarone) infusion post-cardioversion to maintain sinus\n\n**Anticoagulation consideration:**\n• If AF duration >48 hours and not anticoagulated, consider TEE first\n• Or anticoagulate for ≥3 weeks before elective cardioversion\n• Emergent cardioversion if hemodynamically compromised regardless of duration',
    citation: [1, 2, 3],
    treatment: {
      firstLine: {
        drug: 'Midazolam',
        dose: '3-5 mg',
        route: 'IV',
        frequency: 'Bolus, additional 2 mg q2min PRN',
        duration: 'Until adequate sedation for cardioversion',
        notes: 'For procedural sedation. Flumazenil 0.5-1 mg IV available for reversal.',
      },
      alternative: {
        drug: 'Amiodarone',
        dose: '150 mg bolus, then 1 mg/min infusion',
        route: 'IV',
        frequency: 'Bolus over 10 min, then continuous',
        duration: 'Continue until critical illness resolves',
        notes: 'Post-cardioversion to maintain sinus rhythm.',
      },
      monitoring: 'Rhythm, blood pressure, respiratory status during sedation. Monitor for AF recurrence post-cardioversion.',
    },
    next: 'afib-refractory-reassess',
  },

  // =====================================================================
  // MODULE 2: UNSTABLE PATHWAY
  // =====================================================================

  {
    id: 'afib-unstable-wpw',
    type: 'question',
    module: 2,
    title: 'WPW / Pre-Excitation Screen',
    body: 'Is there evidence of WPW / pre-excitation syndrome?\n\nLook for: irregular wide-complex tachycardia, rate >200, variable QRS morphology, delta waves on prior ECG. WPW + A-Fib is a life-threatening emergency.',
    options: [
      {
        label: 'Yes \u2014 WPW / pre-excitation suspected',
        description: 'Irregular wide-complex tachycardia, delta waves, rate >200',
        next: 'afib-wpw-result',
        urgency: 'critical',
      },
      {
        label: 'No \u2014 No pre-excitation',
        description: 'Standard A-Fib RVR without accessory pathway',
        next: 'afib-cardioversion-protocol',
      },
    ],
  },

  {
    id: 'afib-wpw-result',
    type: 'result',
    module: 2,
    title: 'WPW + A-Fib Management',
    body: 'WPW with atrial fibrillation is a life-threatening emergency.\n\nAV nodal blocking agents are ABSOLUTELY CONTRAINDICATED \u2014 including beta-blockers, calcium channel blockers, digoxin, and IV amiodarone. These agents may paradoxically accelerate ventricular response through the accessory pathway and precipitate ventricular fibrillation.',
    recommendation: 'Immediate [synchronized cardioversion](#/info/cardioversion-afib) (200J biphasic). If cardioversion is not immediately available, [Procainamide](#/drug/procainamide) may be used as a temporizing measure.',
    confidence: 'definitive',
    citation: [2, 3],
    treatment: {
      firstLine: {
        drug: 'Synchronized Cardioversion',
        dose: '200J biphasic',
        route: 'External defibrillator',
        frequency: 'Once, escalate energy if unsuccessful',
        duration: 'Immediate',
        notes: 'First-line treatment for WPW + A-Fib. AV nodal blockers are contraindicated.',
      },
      alternative: {
        drug: 'Procainamide',
        dose: '20-50 mg/min',
        route: 'IV',
        frequency: 'Continuous infusion',
        duration: 'Until arrhythmia resolves, max 17 mg/kg',
        notes: 'Use only if cardioversion not immediately available. Hold if QRS widens >50% or hypotension.',
      },
      monitoring: 'Continuous cardiac monitoring. Watch for conversion to VF. Have defibrillator ready.',
    },
  },

  {
    id: 'afib-cardioversion-protocol',
    type: 'info',
    module: 2,
    title: 'Synchronized Cardioversion Protocol',
    body: 'SYNCHRONIZED CARDIOVERSION PROTOCOL\n\n1. PREPARATION\n\u2022 Confirm synchronization is enabled on defibrillator\n\u2022 Apply pads: anterior/lateral placement preferred (EPIC trial)\n\u2022 Hyperinflation may impair conduction \u2014 cardiovert at end-expiration if possible\n\n2. SEDATION\n\u2022 Midazolam 3\u20135 mg IV bolus, additional 2 mg q2min PRN to adequate sedation\n\u2022 Alternative: MidaKet for patients resistant to midazolam\n\u2022 Flumazenil 0.5\u20131 mg IV available for reversal\n\n3. CARDIOVERSION\n\u2022 Start at 200J biphasic (use maximal energy available)\n\u2022 Escalate energy if initial attempt unsuccessful\n\n4. POST-CARDIOVERSION\n\u2022 Consider [Amiodarone](#/drug/amiodarone) to maintain sinus rhythm (150mg IV bolus, then 1 mg/min infusion)\n\u2022 Consider IV [Magnesium Sulfate](#/drug/magnesium-sulfate) 2\u20134g to enhance cardioversion success\n\u2022 If cardioversion not immediately feasible, IV [Amiodarone](#/drug/amiodarone) may be used as temporizing measure',
    citation: [1, 2, 5],
    treatment: {
      firstLine: {
        drug: 'Midazolam',
        dose: '3-5 mg',
        route: 'IV',
        frequency: 'Bolus, additional 2 mg q2min PRN',
        duration: 'Until adequate sedation',
        notes: 'For procedural sedation. Flumazenil 0.5-1 mg IV available for reversal.',
      },
      alternative: {
        drug: 'Amiodarone',
        dose: '150 mg bolus, then 1 mg/min infusion',
        route: 'IV',
        frequency: 'Bolus over 10 min, then continuous',
        duration: 'Continue post-cardioversion to maintain sinus',
        notes: 'IV Magnesium 2-4g may enhance cardioversion success.',
      },
      monitoring: 'Respiratory status during sedation. Cardiac rhythm post-cardioversion. Watch for AF recurrence.',
    },
    next: 'afib-cardioversion-result',
  },

  {
    id: 'afib-cardioversion-result',
    type: 'result',
    module: 2,
    title: 'Post-Cardioversion Management',
    body: 'Patient has undergone or is undergoing cardioversion for hemodynamically unstable A-Fib RVR.',
    recommendation: 'Continue [Amiodarone](#/drug/amiodarone) infusion to prevent recurrence. Monitor for reversion to A-Fib. Treat underlying precipitants (sepsis, PE, electrolyte abnormalities). Consider anticoagulation assessment once stabilized.',
    confidence: 'recommended',
    citation: [1],
    treatment: {
      firstLine: {
        drug: 'Amiodarone',
        dose: '150 mg bolus, then 1 mg/min infusion',
        route: 'IV',
        frequency: 'Continuous infusion',
        duration: 'Until critical illness resolves',
        notes: 'Continue infusion to prevent AF recurrence. May re-bolus 150 mg PRN.',
      },
      monitoring: 'Continuous cardiac monitoring for AF recurrence. Treat underlying precipitants (sepsis, PE, electrolyte abnormalities).',
    },
  },

  // =====================================================================
  // MODULE 3: STABLE \u2014 RATE CONTROL
  // =====================================================================

  {
    id: 'afib-stable-drugs',
    type: 'info',
    module: 3,
    title: 'First-Line Rate Control Agents',
    body: 'FIRST-LINE AGENTS FOR RATE CONTROL\n\nBeta-Blockers (Class 1 recommendation):\n\u2022 [Metoprolol](#/drug/metoprolol) \u2014 2.5\u20135 mg IV q5min, up to 15 mg total\n\u2022 [Esmolol](#/drug/esmolol) \u2014 Ultra-short-acting, ideal when rapid titration needed\n\u2022 Safe in COPD (multiple studies confirm no adverse respiratory effects)\n\u2022 Preferred in CAD or compensated HFrEF\n\u2022 Use cautiously in decompensated heart failure\n\nCalcium Channel Blockers:\n\u2022 [Diltiazem](#/drug/diltiazem) \u2014 0.25 mg/kg IV bolus, onset within minutes\n\u2022 [Verapamil](#/drug/verapamil) \u2014 Alternative CCB, less commonly used\n\u2022 90% rate control vs 74% with amiodarone or digoxin\n\u2022 \u26a0\ufe0f CONTRAINDICATED if EF \u226440% or decompensated HF (Class 3: Harm)\n\u2022 Obtain echo or check history for EF if unknown\n\nAdjunctive:\n\u2022 IV [Magnesium Sulfate](#/drug/magnesium-sulfate) \u2014 Reasonable to add (Class 2a). Blocks slow Ca channels at AV node with minimal toxicity.\n\n\u26a0\ufe0f Do NOT combine beta-blockers with calcium channel blockers \u2014 risk of synergistic hypotension.',
    citation: [1, 2, 4],
    treatment: {
      firstLine: {
        drug: 'Diltiazem',
        dose: '0.25 mg/kg',
        route: 'IV',
        frequency: 'Bolus, may repeat in 15 min',
        duration: 'Until rate controlled',
        notes: 'Onset within minutes. 90% rate control. Contraindicated if EF ≤40% or decompensated HF.',
      },
      alternative: {
        drug: 'Metoprolol',
        dose: '2.5-5 mg',
        route: 'IV',
        frequency: 'q5min',
        duration: 'Up to 15 mg total',
        notes: 'Safe in COPD. Preferred in CAD or compensated HFrEF. Use cautiously in decompensated HF.',
      },
      monitoring: 'Heart rate, blood pressure. Do NOT combine beta-blockers with CCBs (synergistic hypotension). IV Magnesium 2-4g may be added as adjunct.',
    },
    next: 'afib-rate-controlled',
  },

  {
    id: 'afib-rate-controlled',
    type: 'question',
    module: 3,
    title: 'Rate Control Assessment',
    body: 'Is the ventricular rate now controlled?\n\nTarget heart rate:\n\u2022 ICU / critically ill: <130 bpm may be reasonable\n\u2022 Outpatient / stable: <100\u2013110 bpm (RACE II trial)\n\u2022 Titrate primarily to control symptoms rather than strict targets\n\u2022 Some patients may benefit from mild compensatory tachycardia \u2014 do not aggressively normalize if rate is due to underlying process',
    options: [
      {
        label: 'Yes \u2014 Rate controlled',
        description: 'Heart rate at target, symptoms improved',
        next: 'afib-onset-assessment',
      },
      {
        label: 'No \u2014 Rate still uncontrolled',
        description: 'Heart rate remains above target despite first-line agent',
        next: 'afib-refractory',
        urgency: 'urgent',
      },
    ],
  },

  // =====================================================================
  // MODULE 4: REFRACTORY RATE CONTROL
  // =====================================================================

  {
    id: 'afib-refractory',
    type: 'question',
    module: 4,
    title: 'Refractory Rate Control',
    body: 'Select second-line intervention for refractory rate control.\n\nFirst-line agent was insufficient. Re-evaluate for underlying causes (sepsis, hypovolemia, pain, PE). Ensure adequate trial of first-line agent before escalating.\n\n\u26a0\ufe0f Avoid combining beta-blockers with calcium channel blockers.',
    options: [
      {
        label: 'Add IV Magnesium',
        description: 'Blocks slow Ca channels at AV node. Excellent safety profile.',
        next: 'afib-refractory-mg',
      },
      {
        label: 'Add Digoxin',
        description: 'Adjunctive when hypotension limits beta-blocker/CCB titration.',
        next: 'afib-refractory-dig',
      },
      {
        label: 'Switch to Amiodarone',
        description: 'More hemodynamically stable. May achieve cardioversion.',
        next: 'afib-refractory-amio',
      },
      {
        label: 'Consider Rhythm Control',
        description: 'When rate control strategy has failed.',
        next: 'afib-rhythm-control',
      },
    ],
  },

  {
    id: 'afib-refractory-mg',
    type: 'info',
    module: 4,
    title: 'Add IV Magnesium',
    body: 'IV [Magnesium Sulfate](#/drug/magnesium-sulfate)\n\n\u2022 2\u20134 grams IV bolus, may follow with continuous infusion\n\u2022 Blocks slow calcium channels in SA and AV nodes\n\u2022 Minimal toxicity \u2014 one meta-analysis detected no adverse events\n\u2022 Even if cardioversion doesn\u2019t occur, magnesium reduces heart rate and augments efficacy of other antiarrhythmics\n\u2022 Contraindicated if GFR <30 mL/min or oliguria \u2014 use intermittent boluses instead\n\u2022 Target serum level ~3\u20134 mg/dL for optimal antiarrhythmic effect',
    citation: [1, 6],
    treatment: {
      firstLine: {
        drug: 'Magnesium Sulfate',
        dose: '2-4 grams',
        route: 'IV',
        frequency: 'Bolus, may follow with continuous infusion',
        duration: 'Target serum level 3-4 mg/dL',
        notes: 'Blocks slow Ca channels at SA/AV nodes. Minimal toxicity. Augments efficacy of other antiarrhythmics.',
      },
      monitoring: 'Serum magnesium level (target 3-4 mg/dL). Contraindicated if GFR <30 mL/min or oliguria - use intermittent boluses instead.',
    },
    next: 'afib-refractory-reassess',
  },

  {
    id: 'afib-refractory-dig',
    type: 'info',
    module: 4,
    title: 'Add Digoxin',
    body: '[Digoxin](#/drug/digoxin)\n\n\u2022 Useful when hypotension limits further titration of beta-blockers or CCBs\n\u2022 Slow onset: ~3 hours to achieve rate control (vs 5 min for diltiazem)\n\u2022 Limited efficacy during exertion \u2014 slows primarily resting heart rate\n\u2022 \u26a0\ufe0f Post hoc analyses associate digoxin with increased mortality in A-Fib\n\u2022 Use at low doses, typically in combination with other AV nodal agents\n\u2022 May be particularly useful in patients with concurrent heart failure',
    citation: [1, 2, 3],
    treatment: {
      firstLine: {
        drug: 'Digoxin',
        dose: '0.25-0.5 mg',
        route: 'IV',
        frequency: 'Once',
        duration: 'Onset ~3 hours',
        notes: 'Useful when hypotension limits BB/CCB titration. Use low doses. Slows primarily resting HR.',
      },
      monitoring: 'Heart rate, digoxin level (if continued). Caution: post hoc analyses associate with increased mortality in A-Fib. Use in combination with other AV nodal agents.',
    },
    next: 'afib-refractory-reassess',
  },

  {
    id: 'afib-refractory-amio',
    type: 'info',
    module: 4,
    title: 'Switch to Amiodarone',
    body: '[Amiodarone](#/drug/amiodarone)\n\n\u2022 Load with 150 mg IV bolus over 10 min, then 1 mg/min infusion\n\u2022 May need to re-bolus 150 mg x2\u20133 (total 150\u2013450 mg in boluses)\n\u2022 More hemodynamically stable than beta-blockers or CCBs\n\u2022 May achieve chemical cardioversion \u2014 beneficial if rhythm control desired\n\u2022 74% rate control achieved in clinical trials\n\u2022 \u26a0\ufe0f Do not conclude amiodarone has failed without adequate re-bolusing\n\u2022 If cardioversion occurs, continue infusion until critical illness resolves',
    citation: [1, 2, 5],
    treatment: {
      firstLine: {
        drug: 'Amiodarone',
        dose: '150 mg bolus, then 1 mg/min infusion',
        route: 'IV',
        frequency: 'Bolus over 10 min, then continuous',
        duration: 'Continue until rate controlled or critical illness resolves',
        notes: 'May need to re-bolus 150 mg x2-3 (total 150-450 mg in boluses). Do not conclude failure without adequate re-bolusing.',
      },
      monitoring: '74% rate control in trials. More hemodynamically stable than BBs or CCBs. May achieve chemical cardioversion.',
    },
    next: 'afib-refractory-reassess',
  },

  {
    id: 'afib-rhythm-control',
    type: 'info',
    module: 4,
    title: 'Consider Rhythm Control',
    body: 'RHYTHM CONTROL STRATEGY\n\nConsider when rate control strategy has failed or in new-onset AF where conversion is desirable.\n\nStepwise approach:\n1. IV [Magnesium Sulfate](#/drug/magnesium-sulfate) infusion (front-line, excellent safety)\n2. [Amiodarone](#/drug/amiodarone) if magnesium alone insufficient\n3. DC cardioversion (especially in intubated patients)\n\nFactors favoring rhythm control:\n\u2022 New-onset AF (NOAF) \u2014 likely to revert\n\u2022 Pulmonary hypertension, mitral stenosis, diastolic dysfunction\n\u2022 Heart failure with reduced EF\n\u2022 Failure of rate control\n\nFactors favoring rate control:\n\u2022 Chronic/longstanding AF\n\u2022 Onset >48 hours without anticoagulation\n\u2022 Ongoing severe physiological stress',
    citation: [1, 3, 7],
    treatment: {
      firstLine: {
        drug: 'Magnesium Sulfate',
        dose: '2-4 grams',
        route: 'IV',
        frequency: 'Bolus, then continuous infusion',
        duration: 'Target serum 3-4 mg/dL',
        notes: 'Front-line for rhythm control. Excellent safety profile.',
      },
      alternative: {
        drug: 'Amiodarone',
        dose: '150 mg bolus, then 1 mg/min infusion',
        route: 'IV',
        frequency: 'Continuous',
        duration: 'Until cardioversion or rate control',
        notes: 'Add if magnesium alone insufficient. DC cardioversion if both fail (especially in intubated patients).',
      },
      monitoring: 'Rhythm for conversion. Factors favoring rhythm control: NOAF, pulmonary HTN, mitral stenosis, HFrEF, rate control failure.',
    },
    next: 'afib-refractory-reassess',
  },

  {
    id: 'afib-refractory-reassess',
    type: 'question',
    module: 4,
    title: 'Post-Intervention Reassessment',
    body: 'Is the rate now controlled after second-line intervention?',
    options: [
      {
        label: 'Yes \u2014 Rate controlled',
        description: 'Heart rate at target, symptoms improved',
        next: 'afib-onset-assessment',
      },
      {
        label: 'No \u2014 Still refractory',
        description: 'Consider combining agents or rhythm control if not yet attempted',
        next: 'afib-refractory',
        urgency: 'urgent',
      },
    ],
  },

  // =====================================================================
  // MODULE 5: AF ONSET & ANTICOAGULATION
  // =====================================================================

  {
    id: 'afib-onset-assessment',
    type: 'question',
    module: 5,
    title: 'AF Onset Assessment',
    body: 'Is this new-onset AF or known/chronic AF?\n\nDistinguishing onset is important for anticoagulation decisions and rhythm control candidacy.\n\nNew-onset AF (NOAF): First episode, occurring during current hospitalization or acute illness. Often reverts spontaneously as underlying cause resolves.\n\nKnown/Chronic AF: Pre-existing AF documented prior to current presentation, or AF duration >48 hours.',
    options: [
      {
        label: 'New-onset AF (NOAF)',
        description: 'First episode during current illness/hospitalization',
        next: 'afib-noaf-anticoag',
      },
      {
        label: 'Known/Chronic AF or onset >48 hours',
        description: 'Pre-existing AF or duration exceeds 48 hours',
        next: 'afib-cha2ds2vasc',
      },
    ],
  },

  {
    id: 'afib-noaf-anticoag',
    type: 'info',
    module: 5,
    title: 'NOAF \u2014 Anticoagulation Considerations',
    body: 'NEW-ONSET AF IN CRITICAL ILLNESS\n\nAnticoagulation is generally NOT recommended for NOAF:\n\u2022 Retrospective studies show anticoagulation increases bleeding risk without reducing stroke incidence\n\u2022 Most patients with NOAF will revert to sinus rhythm as critical illness resolves\n\u2022 Survey of UK intensivists: 64% do not routinely anticoagulate NOAF\n\nExceptions \u2014 consider anticoagulation if:\n\u2022 AF persists >48 hours\n\u2022 High stroke risk with low bleeding risk\n\u2022 AF continues beyond resolution of acute illness\n\nIf AF persists for weeks, reassess with [CHA\u2082DS\u2082-VASc scoring](#/calculator/cha2ds2vasc) as chronic AF management becomes appropriate.',
    citation: [3, 8, 9],
    next: 'afib-disposition',
  },

  {
    id: 'afib-cha2ds2vasc',
    type: 'info',
    module: 5,
    title: 'CHA\u2082DS\u2082-VASc Assessment',
    body: 'ANTICOAGULATION FOR KNOWN/CHRONIC AF\n\nAssess stroke risk using [CHA\u2082DS\u2082-VASc score](#/calculator/cha2ds2vasc):\n\nAnticoagulation Recommendations:\n\u2022 Score \u22652 (men) or \u22653 (women) \u2192 Anticoagulate (strong recommendation)\n\u2022 Score 1 (men) or 2 (women) \u2192 Consider anticoagulation\n\u2022 Score 0 (men) or 1 (women) \u2192 May omit anticoagulation\n\nPreferred agents: [Apixaban](#/drug/apixaban/atrial fibrillation), [Rivaroxaban](#/drug/rivaroxaban/atrial fibrillation) (DOACs preferred over warfarin)\n\n\u26a0\ufe0f If AF duration >48 hours and patient is NOT anticoagulated:\n\u2022 Consider TEE to exclude left atrial appendage thrombus before cardioversion\n\u2022 Or initiate anticoagulation for \u22653 weeks before elective cardioversion',
    calculatorLinks: [
      { id: 'cha2ds2vasc', label: 'Calculate CHA\u2082DS\u2082-VASc' },
    ],
    citation: [1, 3, 10],
    treatment: {
      firstLine: {
        drug: 'Apixaban',
        dose: '5 mg (2.5 mg if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5)',
        route: 'PO',
        frequency: 'BID',
        duration: 'Long-term',
        notes: 'Preferred DOAC for AF anticoagulation. Consider CHA₂DS₂-VASc score for indication.',
      },
      alternative: {
        drug: 'Rivaroxaban',
        dose: '20 mg (15 mg if CrCl 15-50)',
        route: 'PO',
        frequency: 'Daily with evening meal',
        duration: 'Long-term',
        notes: 'Alternative DOAC. Take with food for optimal absorption.',
      },
      monitoring: 'Renal function, bleeding signs. If AF >48h and not anticoagulated, consider TEE before cardioversion or anticoagulate ≥3 weeks before elective cardioversion.',
    },
    next: 'afib-disposition',
  },

  // =====================================================================
  // MODULE 6: DISPOSITION
  // =====================================================================

  {
    id: 'afib-disposition',
    type: 'result',
    module: 6,
    title: 'A-Fib RVR \u2014 Disposition & Follow-Up',
    body: 'DISPOSITION CONSIDERATIONS\n\n\u2022 Continue rate control agent that achieved control\n\u2022 Target resting HR <100\u2013110 bpm for outpatient management\n\u2022 Assess heart rate response during exertion (ambulatory monitoring or brisk walk)\n\u2022 Ensure electrolytes are corrected (K\u207a, Mg\u00b2\u207a)\n\u2022 Address underlying precipitants\n\u2022 Cardiology follow-up for: new-onset AF, rhythm control consideration, AV node ablation candidacy\n\u2022 For patients with refractory symptoms despite optimal medical therapy, AV node ablation with permanent pacemaker may be considered',
    recommendation: 'Disposition based on clinical stability and rate control achieved. Ensure anticoagulation addressed per [CHA\u2082DS\u2082-VASc](#/calculator/cha2ds2vasc). Arrange cardiology follow-up. Review [Discharge Instructions](#/info/afib-discharge) with patient before discharge.',
    confidence: 'recommended',
    citation: [1, 2, 3],
  },

];

export const AFIB_RVR_NODE_COUNT = AFIB_RVR_NODES.length;

// -------------------------------------------------------------------
// Module Labels (for flowchart progress bar)
// -------------------------------------------------------------------

export const AFIB_RVR_MODULE_LABELS = [
  'Initial Assessment',
  'Unstable Pathway',
  'Rate Control',
  'Refractory',
  'Anticoagulation',
  'Disposition',
];

// -------------------------------------------------------------------
// Evidence Citations
// -------------------------------------------------------------------

export const AFIB_RVR_CITATIONS: Citation[] = [
  { num: 1, text: 'Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. J Am Coll Cardiol. 2024;83(1):109-279.' },
  { num: 2, text: 'Wigginton JG, Agarwal S, et al. Part 9: Adult Advanced Life Support: 2025 AHA Guidelines for CPR and ECC. Circulation. 2025;152(16_suppl_2):S538-S577.' },
  { num: 3, text: 'Ko D, Chung MK, et al. Atrial Fibrillation: A Review. JAMA. 2025;333(4):329-342.' },
  { num: 4, text: 'Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of Atrial Fibrillation. JAMA. 2015;314(3):278-88.' },
  { num: 5, text: 'Panchal AR, Bartos JA, et al. Part 3: Adult Basic and Advanced Life Support: 2020 AHA Guidelines for CPR and ECC. Circulation. 2020;142(16_suppl_2):S366-S468.' },
  { num: 6, text: 'Michaud GF, Stevenson WG. Atrial Fibrillation. N Engl J Med. 2021;384(4):353-361.' },
  { num: 7, text: 'Bosch NA, Cimini J, Walkey AJ. Atrial Fibrillation in the ICU. Chest. 2018;154(6):1424-1434.' },
  { num: 8, text: 'Chyou JY, Barkoudah E, et al. Atrial Fibrillation Occurring During Acute Hospitalization: AHA Scientific Statement. Circulation. 2023;147(15):e676-e698.' },
  { num: 9, text: 'Long B, Brady WJ, Gottlieb M. Emergency Medicine Updates: Atrial Fibrillation with Rapid Ventricular Response. Am J Emerg Med. 2023;74:57-64.' },
  { num: 10, text: 'Wolfes J, Ellermann C, et al. Comparison of Latest ESC, ACC/AHA/ACCP/HRS, and CCS Guidelines on AF Management. JACC Clin Electrophysiol. 2025;11(4):836-849.' },
];
